InVivo Therapeutics

Nano cap InVivo Therapeutics (OTCQB:NVIV) continued its up move today with shares rising38%on a 10x surge in volume. Prices have almost tripled in a month as investor interest builds over its Neuro-Spinal Scaffold for the treatment of acute spinal cord injury. The first patient to receive the device is a 25-year old Scottsdale, AZ man who broke his back in a dirt bike accident last month. Although it's too early to gauge the success of the implant some researchers and clinicians believe it has great promise. In late October, the FDA approved an expansion of clinical trial sites from six to 20 and broadened patient eligibility criteria. After today's action, InVivo's market cap is $133M which is comparable to other regenerative medicine firms working on spinal cord injury therapies. For comparison purposes, the market valuations of Neuralstem (NYSEMKT:CUR), Asterias Biotherapeutics (NYSEMKT:AST) and StemCells (NASDAQ:STEM) are $256M, $125M and $80M, respectively. Share this with a colleague

Go here to see the original:
InVivo Therapeutics